SLC2A1 and cancer: Among small-molecule GLUT1 inhibitors [23,26,27,28,29,30,31,32], STF-31 [23] and WZB117 [26] were reported to inhibit GLUT1-mediated glucose uptake at low μM concentrations and to show some anti-cancer activities in xenograft tumor models.